Literature DB >> 17876850

Impact of psychogenic movement disorders versus Parkinson's on disability, quality of life, and psychopathology.

Karen E Anderson1, Ann L Gruber-Baldini, Christopher G Vaughan, Stephen G Reich, Paul S Fishman, William J Weiner, Lisa M Shulman.   

Abstract

Patients with psychogenic movement disorders (PMD) often report severe impairment, yet the impact of PMD on disability and quality of life has not been examined. We compared 66 patients with PMD and 704 patients with Parkinson's disease (PD) on measures of disability (Older Americans Resources and Services Scale, OARS); quality of life (QOL; SF-12v2 Health Survey) and psychiatric symptomatology (Brief Symptom Inventory 18, BSI-18). On the total OARS, PMD and PD patients reported similar levels of disability (17.6 +/- 6.6, 19.8 +/- 10.9, P = 0.490 at "best" function and 24.1 +/- 11.2, 26.2 +/- 14.3, P = 0.497 at their "worst" function). PMD patients reported similar Physical Health QOL to PD patients (38.9 +/- 14.5, 39.8 +/- 11.6, P = 0.652) but worse mental health QOL (41.6 +/- 13.4 vs. 48.9 +/- 11.0, P < 0.001). On the BSI-18, PMD patients reported higher levels of distress on the Global Symptom Index (62.03 +/- 9.6 vs. 53.7 +/- 9.9, P < 0.001) and on Anxiety, Depression and Somatization subscales (PMD vs. PD scores: Anxiety 58.9 +/- 12.0 vs. 52.3 +/- 10.1, P < 0.001; Depression 58.8 +/- 11.9 vs. 51.3 +/- 10.3, P < 0.001; Somatization 60.5 +/- 11.0 vs. 54.7 +/- 8.7, P < 0.001). Thus, severity of disability reported by the PMD group was equal to that seen in a progressive neurodegenerative condition. Quality of life and mental health implications of PMD were also evident. PMD impacts several aspects of patient function and daily life. (c) 2007 Movement Disorder Society.

Entities:  

Mesh:

Year:  2007        PMID: 17876850     DOI: 10.1002/mds.21687

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  26 in total

Review 1.  Functional (psychogenic) movement disorders.

Authors:  Kathrin Czarnecki; Mark Hallett
Journal:  Curr Opin Neurol       Date:  2012-08       Impact factor: 5.710

2.  Psychopathology and psychogenic movement disorders.

Authors:  Sarah Kranick; Vindhya Ekanayake; Valeria Martinez; Rezvan Ameli; Mark Hallett; Valerie Voon
Journal:  Mov Disord       Date:  2011-06-28       Impact factor: 10.338

3.  Treatment of functional motor disorders.

Authors:  Jeannette M Gelauff; Yasmine E M Dreissen; Marina A J Tijssen; Jon Stone
Journal:  Curr Treat Options Neurol       Date:  2014-04       Impact factor: 3.598

4.  Fatigue, not self-rated motor symptom severity, affects quality of life in functional motor disorders.

Authors:  J M Gelauff; E M Kingma; J S Kalkman; R Bezemer; B G M van Engelen; J Stone; M A J Tijssen; J G M Rosmalen
Journal:  J Neurol       Date:  2018-06-02       Impact factor: 4.849

Review 5.  [Clinical and cognitive aspects of functional (psychogenic) tremor].

Authors:  K E Zeuner; R Schmidt; P Schwingenschuh
Journal:  Nervenarzt       Date:  2018-04       Impact factor: 1.214

Review 6.  Opinion: A role for placebo therapy in psychogenic movement disorders.

Authors:  Karen S Rommelfanger
Journal:  Nat Rev Neurol       Date:  2013-04-30       Impact factor: 42.937

Review 7.  Psychogenic movement disorders.

Authors:  Francesca Morgante; Mark J Edwards; Alberto J Espay
Journal:  Continuum (Minneap Minn)       Date:  2013-10

8.  Functional neurological disorders: acute presentations and management.

Authors:  Hannah R Cock; Mark J Edwards
Journal:  Clin Med (Lond)       Date:  2018-10       Impact factor: 2.659

Review 9.  Functional (psychogenic) movement disorders - Clinical presentations.

Authors:  Mark Hallett
Journal:  Parkinsonism Relat Disord       Date:  2015-09-03       Impact factor: 4.891

10.  Impaired resting vagal tone in patients with functional movement disorders.

Authors:  Carine W Maurer; Victoria D Liu; Kathrin LaFaver; Rezvan Ameli; Tianxia Wu; Ryan Toledo; Steven A Epstein; Mark Hallett
Journal:  Parkinsonism Relat Disord       Date:  2016-06-16       Impact factor: 4.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.